Zhejiang Cheng Yi Pharmaceutical (SHA:603811) passed Australia's Therapeutic Goods Administration-Good Manufacturing Practice certification for two active pharmaceutical ingredients (API).
Azathioprine API is mainly used for immunosuppression and treating tumors, while mercaptopurine API is an anti-tumor compound, according to a Jan. 10 filing with the Shanghai bourse.